Cartesian Therapeutics Inc (RNAC) FinancialsRNACCartesian Therapeutics Inc

Evaluating the bottom line, Cartesian Therapeutics, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -71351.28%, while the net margin is -30016.67%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively RNAC converts its operational activities into shareholder value.

In the context of the broader market, RNAC competes directly with industry leaders such as CRDL and DTIL. With a market capitalization of $206.37M, it holds a significant position in the sector. When comparing efficiency, RNAC's gross margin of 100.00% stands against CRDL's N/A and DTIL's N/A. Such benchmarking helps identify whether Cartesian Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

The company has shown inconsistent revenue, with a significant drop to $0 in Q2 2026 after reporting $1,100,000 in Q1 2025. The gross margin remains strong at 100%, but net income has been negative, with a loss of $39,182,000 in Q1 2026 and a loss of $12,523,000 in Q2 2026.